Ciprofloxacin Lactate Sodium Chloride Injection

It has a broad-spectrum antibacterial effect, especially against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, etc., Enterobacter, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococci, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial effect against Chlamydia trachomatis, Mycoplasma, Legionella, and also against Mycobacterium tuberculosis and atypical mycobacteria.

The main ingredients of this product are: Ciprofloxacin lactate Chemical name: 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7 (1-piperazinyl)-3-quinolinecarboxylic acid lactate Molecular formula: C17H18FN3O3C3H6O3 Molecular weight: 421.43

For use in cases caused by sensitive bacteria: 1. Urinary and reproductive system infections, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute onset of bronchial infection and lung infection caused by sensitive Gram-negative bacilli. 3. Gastrointestinal tract infections caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis.

This product is for intravenous drip administration. For any patient, the dosage should be determined according to the degree and nature of the infection, the sensitivity of the pathogen, the patient's body resistance, and liver and kidney function. The general dosage for adults is 0.1-0.2g per day, intravenously dripped once every 12 hours, and the drip time for each 0.2g is at least 30 minutes. For severe infections or Pseudomonas aeruginosa infections, the dose can be increased to 0.4g per day, 2-3 times a day. The course of treatment depends on the severity of the infection. Usually the treatment lasts 7-14 days, and it should generally be continued for at least 2 days after the symptoms of infection disappear. Urinary tract infection: 5-7 days for acute simple lower urinary tract infection; 7-14 days for complicated urinary tract infection, pneumonia and skin and soft tissue infection: 7-14 days; intestinal infection: 5-7 days; bone and joint infection: 4-6 weeks or

1 Gastrointestinal reactions are common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2 Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3 Allergic reactions: rash, itchy skin, occasionally exudative erythema multiforme and angioneurotic edema. A few patients have photosensitivity reactions. 4 Occasionally, 1. Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors. 2. Interstitial nephritis manifestations such as hematuria, fever, and rash. 3. Phlebitis. 4. Crystalluria, more common when used in high doses. 5. Joint pain. 5 A small number of patients may experience elevated serum aminotransferase, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients with a history of allergy to this product or any fluoroquinolone are contraindicated.

1 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 When this product is used in combination with theophylline, competitive inhibition with the cytochrome P450 binding site may lead to a significant reduction in the hepatic clearance of theophylline, prolonged blood elimination half-life, increased blood concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, agitation, convulsions, palpitations, etc. Therefore, theophylline blood concentration should be measured and the dose adjusted when used in combination. 3 The combined use of cyclosporine and this product can increase the blood concentration of the former. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4 When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter. The patient's prothrombin time should be closely monitored when used in combination. 5 Probenecid can reduce the secretion of this product from the renal tubules by about 50%.

Keep in a light-proof and airtight container.

100 ml: 0.2 g